[Bloomberg] — A unit of Japanese drugmaker Astellas Pharma will pay the U.S. government $7.3 million to resolve claims it illegally marketed its antifungal drug Mycamine for children before that use was approved. The U.S. Department of Justice says Astellas’ illegal marketing took place between 2005 and 2010. Mycamine was approved for use in adults […]
AJOB
Target Articles:
Transferring Morality to Human–Nonhuman Chimeras
Ethical Review of Health Systems Research in Low- and Middle-Income Countries: A Conceptual Exploration
Correspondence:
Changing the Discourse on Health Systems Research: Response to Open Peer Commentaries on “Ethical Review of Health Systems Research in Low- and Middle-Income Countries: A Conceptual Exploration”